Updated on June 12th at
The FDA has asked Endo Pharmaceuticals to remove an opioid pain medication, reformulated extended-release oxymorphone hydrochloride (Opana ER), from the market due to "concern that the benefits of the drug may no longer outweigh its risks."
This marks the first time that the FDA has requested a company remove its opioid pain medication from the market as a result of public health concerns for abuse. The agency reached its decision after reviewing postmarketing